These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22395225)

  • 21. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis.
    Shen B; Fazio VW; Remzi FH; Bennett AE; Lopez R; Brzezinski A; Oikonomou I; Sherman KK; Lashner BA
    Dis Colon Rectum; 2007 Apr; 50(4):498-508. PubMed ID: 17279300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis.
    Calabrese C; Fabbri A; Gionchetti P; Rizzello F; Morselli C; Liguori G; Poggioli G; Campieri M; Di Febo G
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1311-6. PubMed ID: 17509099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease.
    Turner D; Wolters VM; Russell RK; Shakhnovich V; Muise AM; Ledder O; Ngan B; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 May; 56(5):492-7. PubMed ID: 23221994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.
    Selvasekar CR; Cima RR; Larson DW; Dozois EJ; Harrington JR; Harmsen WS; Loftus EV; Sandborn WJ; Wolff BG; Pemberton JH
    J Am Coll Surg; 2007 May; 204(5):956-62; discussion 962-3. PubMed ID: 17481518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Biological Therapy in Chronic Antibiotic Refractory Pouchitis: A Systematic Review With Meta-analysis.
    Chandan S; Mohan BP; Kumar A; Khan SR; Chandan OC; Kassab LL; Ponnada S; Kochhar GS
    J Clin Gastroenterol; 2021 Jul; 55(6):481-491. PubMed ID: 34049383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis.
    Philpott J; Ashburn J; Shen B
    Inflamm Bowel Dis; 2017 Jan; 23(1):E5-E6. PubMed ID: 27930413
    [No Abstract]   [Full Text] [Related]  

  • 31. Adalimumab in active ulcerative colitis: a "real-life" observational study.
    ; Armuzzi A; Biancone L; Daperno M; Coli A; Pugliese D; Annese V; Aratari A; Ardizzone S; Balestrieri P; Bossa F; Cappello M; Castiglione F; Cicala M; Danese S; D'Incà R; Dulbecco P; Feliciangeli G; Fries W; Genise S; Gionchetti P; Gozzi S; Kohn A; Lorenzetti R; Milla M; Onali S; Orlando A; Papparella LG; Renna S; Ricci C; Rizzello F; Sostegni R; Guidi L; Papi C
    Dig Liver Dis; 2013 Sep; 45(9):738-43. PubMed ID: 23683530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
    Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
    Mocciaro F; Orlando A; Scimeca D; Cottone M
    Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
    Chaparro M; Burgueño P; Iglesias E; Panés J; Muñoz F; Bastida G; Castro L; Jiménez C; Mendoza JL; Barreiro-de Acosta M; Senent SG; Gomollón F; Calvet X; García-Planella E; Gómez M; Hernández V; Hinojosa J; Mañosa M; Nyssen OP; Gisbert JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):275-83. PubMed ID: 22142227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus.
    Herrlinger KR; Barthel DN; Schmidt KJ; Büning J; Barthel CS; Wehkamp J; Stange EF; Fellermann K
    Aliment Pharmacol Ther; 2010 May; 31(9):1036-41. PubMed ID: 20175769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.